Generated by AI
Certara Inc. is a life sciences software and services company focused on biosimulation and model-informed drug development. Certara provides software tools and technology-enabled services that help pharmaceutical, biotechnology, and regulatory organizations model drug behavior, analyze pharmacokinetics and pharmacodynamics, and support clinical development and regulatory submissions. Its offerings include biosimulation platforms, clinical data automation and validation software, regulatory authoring and submission tools, and market access solutions. The company serves organizations across drug discovery, preclinical research, clinical research, and post-approval activities, supporting more data-driven decision-making throughout the drug development lifecycle. Certara Inc. plays a specialized role in the healthcare market by helping customers improve development efficiency, strengthen evidence generation, and navigate complex regulatory requirements.
Website4 Radnor Corporate Center
Radnor, PA, 19087
United States
The latest articles about CERT.
How Certara’s Q3 earnings changed the conversation Certara (CERT) put fresh numbers on the table with its Q3 2026 report, giving investors new data on profitability, software momentum, and the trade off between quarterly strength and year to date losses. Sales for the quarter reached US$94.9 million compared with US$90.89 million a year earlier, while net income was US$5.59 million compared with US$1.53 million. Earnings per share for the period came in at US$0.04 on both a basic and diluted...
Summary of Nov 26's posts. Generated by AI.
No summary yet.
No summary yet.
Summary of Nov 7's posts. Generated by AI.
Investors talking about CERT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.